Details:

Personal Author:
De Cock, Kevin M. ; Holtgrave, David R. ; Janssen, Robert S. ; Smith, Dawn K. ;
De Cock, Kevin M. ; Holtgrave, David R. ; Janssen, Robert S. ; Smith, Dawn K. ; Less -
Corporate Authors:
National Center for HIV, STD, and TB Prevention (U.S.), Division of HIV/AIDS Prevention--Surveillance and Epidemiology. ; Centers for Disease Control and Prevention (U.S.) ;
National Center for HIV, STD, and TB Prevention (U.S.), Division of HIV/AIDS Prevention--Surveillance and Epidemiology. ; Centers for Disease Control and Prevention (U.S.) ; Less -
Description:
The most effective methods for preventing human immunodeficiency virus (HIV) infection are those that protect against exposure to HIV. Preventive behaviors include sexual abstinence, sex only with an uninfected partner, consistent and correct condom use, abstinence from injecting-drug use, and consistent use of sterile equipment by those unable to cease injecting-drug use. Some healthcare providers have proposed offering antiretroviral drugs to persons with unanticipated sexual or injecting-drug-use HIV exposure to prevent transmission. However, because no data exist regarding the efficacy of this therapy for persons with nonoccupational HIV exposure, it should be considered an unproven clinical intervention. Health-care providers and their patients may opt to consider using antiretroviral drugs after nonoccupational HIV exposures that carry a high risk for infection, but only after careful consideration of the potential risks and benefits and with a full awareness of the gaps in current knowledge. To address concerns related to providing antiretroviral agents to persons after nonoccupational HIV exposure, CDC convened a meeting in July 1997 of scientists, public health experts, clinicians, members of professional associations, representatives from industry, ethicists, and members of affected communities. This report reviews the topics raised at the meeting, provides background information on patient management options, and presents considerations for antiretroviral therapy.
Content Notes:
"The following CDC staff members prepared this report: Dawn K. Smith ... [et al.]"--P. ii. Includes bibliographical references (p. 12-14).
Subject:
[+]
Adverse Effects
Anti-HIV Agents
Clinical Trials As Topic
Cost-Benefit Analysis
Drug Effects
Drug Resistance, Microbial
Economics
Etiology
Evaluation Studies As Topic
HIV
HIV Infections
Prevention & Control
Risk-Taking
Sexual Behavior
Substance Abuse, Intravenous
Therapeutic Use
Zidovudine
Anti-HIV Agents/Adverse Effects
Anti-HIV Agents/Economics
Anti-HIV Agents/Therapeutic Use
HIV/Drug Effects
HIV Infections/Etiology
HIV Infections/Prevention & Control
Zidovudine/Therapeutic Use

Series:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 47, no. RR-17;
Pubmed ID:
9763107
Document Type:
Journal Issue ;
Collection(s):
Stephen B. Thacker CDC Library collection
Main Document Checksum:
[+]
urn:sha256:b45d3aca1d5d01f8496972f0eb5b1471c214a6851c2a370eea385fcf46d3ab79
File Type:

Supporting Files

• No Additional Files

More +